APDN: Applied DNA Sciences Forward P/E Multiple
The forward P/E of the business on the GURU.Markets terminal analytical chart demonstrates market expectations, where the 0.00 level reflects the current value. Applied DNA Sciences (APDN) dominates the biosecurity sector thanks to its unique LinearDNA platform. Financial stability is maintained through equity offerings and cost controls. The company's growth relies on government contracts, the demand for PCR labeling, and the cost of nucleic acid synthesis.
Financial and market metric breakdowns for Applied DNA Corp (APDN)
- stock value and consensus price forecast:
- market capitalization information:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio Applied DNA Sciences|APDN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Applied DNA Sciences|APDN - Company Aggregate Debt|Debt to Book Capitalization Ratio Applied DNA Sciences Inc|APDN - Company Long-Term Indebtedness|Company Short-Term Debts Applied DNA Sciences|Quick Liquidity Indicator adnas.com
- earnings and market ratios statistics:
APDN - Final Profit|Expected Profit Applied DNA Sciences|APDN - Business Payback Period|Forward P/E Multiple Applied DNA|APDN - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Applied DNA Sciences Inc|APDN - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Applied DNA Sciences|APDN - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months adnas.com|APDN - Earnings per share growth this year|Earnings growth forecast for next year Applied DNA Sciences
- sales and revenue data:
Summary company analytics:APDN Applied DNA Sciences, Inc.
Applied DNA Sciences diversification into anti-counterfeiting and viral diagnostics requires a precise valuation of future cash flows. By analyzing the company's forward P/E chart, an investor compares current market capitalization with projected earnings, which helps identify asset overheating and eliminates emotional factors when determining the fair value of the stock.
Who Applied DNA Sciences competes with
Future Price to Earnings Tempus Labs (TEM)|Future Price to Earnings QGEN (Qiagen NV)|Forward P/E Multiple IONS (Ionis Pharma)|Market Cap to Projected Earnings Repligen Inc. (RGEN)|Avidity Biosciences - Forward P/E Multiple|Projected Price to Earnings Ratio crisprtx.com|WGS: Forward P/E Multiple|Price to Future Earnings Ratio RARE|Projected Price to Earnings BEAM|SRPT: Future Price to Earnings Multiple|Forward P/E Multiple TWST|10xgenomics.com - Price to Future Earnings Ratio|Future Price to Earnings Intellia Therapeutics, Inc. NTLA|STOK: Price to Future Earnings Ratio|BioLife Corp - Forward P/E Multiple|WVE - Forward P/E Multiple|MAZE (Maze Therapeutics Inc) - Projected Price to Earnings|sionnatx.com - Future Price to Earnings Multiple|Future Price to Earnings Prime Medicine|Taysha Gene Therapies Inc (TSHA) - Market Cap to Projected Earnings|Forward P/E Multiple QURE|Projected Price to Earnings MeiraGTx Corp MGTX|Forward P/E Multiple RGNX (REGENXBIO Inc.)|Market Cap to Projected Earnings solidbio.com (SLDB)|Ocugen - Forward P/E Multiple|Projected Price to Earnings Ratio Pacific Biosciences of California, Inc.|Benitec (BNTC) - Future Price to Earnings|Price to Future Earnings Ratio DSGN|RCKT (Rocket Pharmaceuticals) - Forward P/E Multiple|Projected Price to Earnings 4dmoleculartherapeutics.com (FDMT)|Forward P/E Multiple LXEO|KRRO - Projected Price to Earnings Ratio|Future Price to Earnings Editas EDIT|Market Cap to Projected Earnings Silence Therapeutics Corp (SLN)|ProQR Therapeutics NV - Forward P/E Multiple|CDXS - Forward P/E Multiple|Sangamo Therapeutics, Inc. (SGMO) - Future Price to Earnings|Price to Expected Earnings Ratio NAUT (Nautilus Bio)|MGX (Metagenomi, Inc) - Forward P/E Multiple|Price to Future Earnings Ratio DTIL (Precision BioSciences Inc.)|Future Price to Earnings Generation Bio Co. (GBIO)|boundlessbio.com - Price to Future Earnings Ratio|Forward P/E Multiple XCUR (Exicure)|IMNN: Price to Future Earnings Ratio|PHIO - Future Price to Earnings|MBIO (Mustang Bio, Inc.) - Price to Future Earnings Ratio|RNAZ: Forward P/E Multiple|Bionano Genomics (BNGO) - Forward P/E Multiple|BLUE (bluebird bio) - Forward P/E Multiple|Forward P/E Multiple ImmunoPrecise|Future Price to Earnings Omega (OMGA)|OMIC: Price to Expected Earnings Ratio|Future Price to Earnings Regulus Therapeutics RGLS|SYRS (syros.com) - Price to Expected Earnings Ratio|TBIO - Future Price to Earnings|TCON: Future Price to Earnings|UBX: Forward P/E Multiple
